Bray P F
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Thromb Haemost. 1994 Oct;72(4):492-502.
The characterization of inherited diseases of platelets has provided valuable information about platelet physiology and platelet protein function. Genetic studies on patients with Glanzmann thrombasthenia, the Bernard-Soulier syndrome, and platelet-type von Willebrand disease have been confined to abnormalities of the GPIIb-IIIa and GPIb-IX receptor complexes. The primary molecular technique used in these analyses has been the polymerase chain reaction (PCR). The amplified PCR products are either directly sequenced, or used to screen for abnormal regions of the genes which are then sequenced. This review examines the known mutations in GPIIb-IIIa and GPIb-IX, focusing on those genetic issues which should dictate decisions regarding the approach to identifying molecular defects. The techniques for characterizing mutant alleles in Glanzmann thrombasthenia and Bernard-Soulier syndrome are described and a general strategy is offered. Because mutations resulting in reduced levels of transcripts can be missed when screening RNA, an argument is made for using genomic DNA as the primary material for mutation detection.
血小板遗传性疾病的特征研究为血小板生理学和血小板蛋白功能提供了有价值的信息。对患有Glanzmann血小板无力症、Bernard-Soulier综合征和血小板型血管性血友病的患者进行的基因研究,一直局限于糖蛋白IIb-IIIa和糖蛋白Ib-IX受体复合物的异常。这些分析中使用的主要分子技术是聚合酶链反应(PCR)。扩增的PCR产物要么直接测序,要么用于筛选随后进行测序的基因异常区域。本综述研究了糖蛋白IIb-IIIa和糖蛋白Ib-IX中已知的突变,重点关注那些应决定识别分子缺陷方法的遗传问题。描述了在Glanzmann血小板无力症和Bernard-Soulier综合征中鉴定突变等位基因的技术,并提供了一个总体策略。由于在筛选RNA时可能会遗漏导致转录本水平降低的突变,因此主张使用基因组DNA作为检测突变的主要材料。